Examples of using Randomisation in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Randomisation, double blinding and drop-outs.
Liver biopsy was performed at 1.5 and 3.5 years after randomisation.
Randomisation has been closed since 22nd of May 2006.
Follow-up is intended to be done at 6 weeks,six months and 12 months after randomisation.
Randomisation was stratified by HCV genotype 1, 2, 3, 4, 5, 6 and indeterminate.
Comparison based on population alive and disease free for at least 366 days following randomisation.
Randomisation was stratified by tumour PD-L1 status and M stage M0/M1a/M1b versus M1c.
Adding swaddling to behaviour modification in infant care did not reduce excessivecrying in healthy infants<13 weeks of age at randomisation.
Randomisation was stratified by BRAF and tumour PD-L1 status and best response to prior ipilimumab.
At the time of the finalanalysis(4 years following the last patient randomisation), the median duration of exposure to everolimus was 204.1 weeks range 2 to 278.
Randomisation was stratified by breast cancer type(operable, locally advanced, or inflammatory) and ER or PgR positivity.
Proportions of Subjects in the Once Daily versus Twice Daily Abacavir+Lamivudine Randomisation of ARROW with Plasma HIV-1 RNA< 80 copies/ml: Subgroup Analysis by Formulation.
Randomisation was stratified by prior trastuzumab treatment and number of prior treatments for metastatic disease.
The combined 150 mg and 300 mg/ 2 week treatment group was non inferior to the 405 mg/ 4 week treatment group(exacerbation rates 10% for each group)at 24 weeks after randomisation.
The median time from diagnosis to randomisation was 64 months in the dasatinib group and 52 months in the imatinib group.
Of these patients had a high or very high DRL at baseline; of these, 52%(representing 27% of the total population)continued to have a high or very high DRL at randomisation.
Randomisation was stratified by sites of disease and by time from discontinuation of prior adjuvant anti-oestrogen therapy.
The dose should be doubled if DBPwas greater than 90 mmHg at any visit after randomisation, and changed back if at any subsequent time the investigator thought it appropriate.
At randomisation, 70% of patients were NYHA class II, 24% were class III and 0.7% were class IV.
Patients were followed every 3 months until 4 consecutive, quarterly follow-up endoscopic biopsy results were negative for HGD, and then biannually untilthe last enrolled patient had completed a minimum of 24 months of follow-up evaluations after randomisation.
PFS was defined as the time from randomisation to the earliest date of disease progression or death from any cause, or to the date of censor.
Patients with a history of delirium tremens, hallucinations, seizures, significant psychiatric comorbidity, or significant abnormalities of liver function aswell as those with significant physical withdrawal symptoms at screening or randomisation were excluded.
Randomisation was stratified by geographic region, time to progression from the start of first-line therapy(< 6 months versus≥6 months) and disease measurability.
A total of 1,250 patients underwent PCI within 72 hours after randomisation, in which case they received intravenous unfractionated heparin to maintain an activated clotting time(ACT) of 300-350 seconds.
Randomisation was stratified by the presence or absence of cirrhosis, HCV genotype(1a versus 1b) and response to prior HCV therapy relapse/breakthrough versus non-response.
PFS was defined as the time from randomisation to disease progression or death as assessed by the treating physicians in the study investigator-assessed.
Randomisation was stratified by PD-L1 expression(≥5% vs.< 5% tumour cell membrane expression), BRAF status, and M stage per the American Joint Committee on Cancer(AJCC) staging system.
In a post-hoc subgroup of patients with symptomatic angina at randomisation(n=1507), no safety signal was identified regarding cardiovascular death, hospitalization for acute MI or heart failure ivabradine 12.0% versus placebo 15.5%, p=0.05.
Randomisation was stratified by geographic region, tumour KRAS status(mutant or wild-type), and time to disease progression(TTP) after commencing first-line treatment< 6 months versus≥6 months.
Randomisation was stratified by geographic region(Europe, North America, and Other), prior VEGF/VEGFR-targeted therapy(patients may have received 0 or 1 prior VEGF/VEGFR-targeted therapy), and age≤65 years or> 65 years.